A 72-year-old man with a 3-year history of BPH-related LUTS has been on tamsulosin 0.4 mg daily for 18 months with partial symptom improvement. Repeat uroflowmetry shows peak flow of 10 mL/s (minimal change). Transrectal ultrasound reveals prostate volume of 52 g. PSA is 2.8 ng/mL. He denies acute urinary retention. What is the most appropriate next step in pharmacological management?

Explanation

## Escalation Strategy in BPH: Addition of 5α-Reductase Inhibitor **Key Point:** When α-blocker monotherapy fails to achieve adequate symptom relief in a patient with a large prostate (>40 g) and elevated PSA, addition of a 5α-reductase inhibitor (finasteride or dutasteride) is the evidence-based next step. ### Clinical Rationale for Combination Therapy This patient has: - **Large prostate volume** (52 g) — exceeds the 40 g threshold for 5α-reductase inhibitor use - **Elevated PSA** (2.8 ng/mL) — indicates significant prostate burden - **Inadequate response to α-blocker alone** — peak flow unchanged at 10 mL/s after 18 months - **No acute retention** — medical management still appropriate ### Evidence for Combination Therapy | Parameter | α-Blocker Alone | Finasteride Alone | Combination (α-Blocker + Finasteride) | |-----------|-----------------|-------------------|---------------------------------------| | **Symptom improvement** | 30–40% | 20–30% | 45–50% | | **Prostate shrinkage** | Minimal | 20–30% | 20–30% | | **Progression prevention** | Modest | Good | Excellent (34% reduction) | | **Acute retention risk reduction** | Modest | Good | Excellent | | **Onset of benefit** | 2–4 weeks | 3–6 months | Rapid (α-blocker) + sustained (finasteride) | **High-Yield:** The landmark **MTOPS trial** (Medical Therapy of Prostatic Symptoms) demonstrated that combination therapy reduces symptom progression by 34% compared to α-blocker monotherapy, particularly in men with large prostates and elevated PSA. ### Why Finasteride Now? 1. **Prostate volume >40 g** — finasteride shrinks the prostate by 20–30% over 6 months 2. **PSA >1.4 ng/mL** — indicates significant androgen-dependent growth 3. **Inadequate α-blocker response** — addition of finasteride addresses the obstructive component 4. **Prevents progression** — reduces risk of acute retention and need for surgery by ~50% **Mnemonic: "BIG PROSTATE + FAILED α-BLOCKER = ADD FINASTERIDE"** - **B**rostate >40 g - **I**nadequate response to initial therapy - **G**rowing PSA (>1.4) - **P**rostate shrinkage needed - **R**eduction in retention risk - **O**ptimal outcome with combination - **S**tay on α-blocker (don't switch) - **T**ake finasteride for 3–6 months - **A**chieve better symptom control - **T**reat the large gland - **E**xtend medical management window **Clinical Pearl:** Finasteride takes 3–6 months to show full benefit because it works by shrinking the prostate through androgen suppression. The α-blocker should be continued during this period to maintain symptom relief while finasteride's effect develops. ### Dosing in Combination - **Tamsulosin:** 0.4–0.8 mg once daily (continue) - **Finasteride:** 5 mg once daily (add) ### Alternative: Dutasteride Dutasteride 0.5 mg daily is an alternative to finasteride with similar efficacy but slightly faster onset (4–6 weeks vs. 3–6 months). Both are acceptable choices. [cite:Harrison 21e Ch 297]